J-Pharma Co., Ltd.
J-Pharma Co., Ltd. scores highest on Torque (49) and lowest on Earnings (7). Its PosiPenta is 25.05 out of 100, weaker than most similar companies.
On the Penta Grid this week, J-Pharma Co., Ltd. is Grid #52 of 53 in the Healthcare sector in Japan, and Grid #1,038 of 1,059 in Japan.
Compared with similar companies in the Healthcare sector in Japan.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| J-Pharma Co., Ltd. | 25.05 | 9 | 7 | 39 | 49 | 22 |
| Koken Ltd. | 60.00 | 90 | 80 | 33 | 39 | 58 |
| Yamashita Health Care Holdings,Inc. | 65.52 | 64 | 87 | 70 | 50 | 57 |
| Create Medic Co., Ltd. | 61.79 | 67 | 53 | 79 | 51 | 59 |
| Morishita Jintan Co., Ltd. | 70.43 | 84 | 84 | 68 | 50 | 66 |
| StemRIM | 28.11 | 27 | 23 | 6 | 54 | 31 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -4.97 |
| P/B ratio | 3.44 |
EEarnings
| Trailing EPS | ₹-54.69 |
| Forward EPS | — |
NNitro
| Price | 271.81 |
| 52-week high | 489.74 |
| 52-week low | 157.39 |
| Fall from 52-week high | 44.5% |
TTorque
| Return on equity (ROE) | -73.01% |
| Debt-to-equity | 0.00 |
AAnchor
| Beta (price swings) | — |
| Market cap | ₹488 Cr |
| Insider holding | 8.51% |
| Dividend yield | 0.00% |
Figures as used for the week of 24 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is J-Pharma Co., Ltd.'s PosiPenta score?
J-Pharma Co., Ltd.'s PosiPenta is 25.05 out of 100 for the week of 24 Oct 2026, based on 5 of 5 pillars.
Where does J-Pharma Co., Ltd. stand on the Penta Grid?
On the Penta Grid this week, J-Pharma Co., Ltd. is Grid #52 of 53 in the Healthcare sector in Japan, and Grid #1,038 of 1,059 in Japan.
Which PosiPenta pillar is strongest for J-Pharma Co., Ltd.?
Torque (durability), with a score of 49 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for J-Pharma Co., Ltd.?
Earnings (growth), with a score of 7 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.